pdf   xlsx method abbreviations

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2), ... versus non active control, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 1.00 [0.83, 1.21]< 10%1 study (1/-)50.0 %NAnot evaluable crucial-
progression or deaths (PFS) 0.66 [0.55, 0.79]< 10%1 study (1/-)100.0 %NAnot evaluable important-
objective responses (ORR) 6.02 [1.83, 19.81]> 10%1 study (1/-)99.8 %NAnot evaluable non important-

safety endpoints 00

AE leading to treatment discontinuation (any grade) 11.74 [2.82, 48.89]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
SAE (any grade) 1.13 [0.82, 1.56]< 10%1 study (1/-)23.3 %NAnot evaluable non important-
TRAE leading to death (grade 5) 3.02 [0.15, 60.52]< 10%1 study (1/-)23.8 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons